Mona Razavian
Overview
Explore the profile of Mona Razavian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Natale P, Palmer S, Saglimbene V, Ruospo M, Razavian M, Craig J, et al.
Cochrane Database Syst Rev
. 2022 Feb;
2:CD008834.
PMID: 35224730
Background: Antiplatelet agents are widely used to prevent cardiovascular events. The risks and benefits of antiplatelet agents may be different in people with chronic kidney disease (CKD) for whom occlusive...
2.
Macneil J, Razavian M, Stephen M, Lau H
Urology
. 2017 Nov;
115:29-32.
PMID: 29155188
No abstract available.
3.
Palmer S, Di Micco L, Razavian M, Craig J, Perkovic V, Pellegrini F, et al.
Cochrane Database Syst Rev
. 2013 Mar;
(2):CD008834.
PMID: 23450589
Background: Antiplatelet agents are widely used to prevent cardiovascular events. The risks and benefits of antiplatelet treatment may be different in people with chronic kidney disease (CKD) for whom occlusive...
4.
Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, et al.
Cochrane Database Syst Rev
. 2012 Oct;
10:CD008176.
PMID: 23076940
Background: Chronic kidney disease (CKD) is a significant risk factor for premature cardiovascular disease and death. Increased oxidative stress in people with CKD has been implicated as a potential causative...
5.
Palmer S, Di Micco L, Razavian M, Craig J, Ravani P, Perkovic V, et al.
Am J Kidney Dis
. 2012 Oct;
61(1):112-22.
PMID: 23022428
Background: Hemodialysis vascular access failure occurs often and increases morbidity for people on hemodialysis therapy. Antiplatelet agents may prevent hemodialysis vascular access failure, but potentially may be hazardous in people...
6.
Jiang S, Stewart G, Barnes E, Jardine M, Razavian M, Gallagher M
Semin Dial
. 2012 Sep;
26(3):361-5.
PMID: 22994648
Establishing and maintaining hemodialysis access are major challenges in dialysis patient care. The impact of implementing guideline recommendations around vascular access surveillance, which lacks strong evidence, is poorly understood. We...
7.
Palmer S, Di Micco L, Razavian M, Craig J, Perkovic V, Pellegrini F, et al.
Ann Intern Med
. 2012 Mar;
156(6):445-59.
PMID: 22431677
Background: Antiplatelet agents are used to prevent cardiovascular events; however, treatment effects may differ in persons with chronic kidney disease (CKD) because atherosclerotic disease is less prevalent, whereas bleeding hazards...
8.
Razavian M, Heeley E, Perkovic V, Zoungas S, Weekes A, Patel A, et al.
Nephrol Dial Transplant
. 2011 Nov;
27(4):1396-402.
PMID: 22053091
Background: Chronic kidney disease (CKD) is common and increasing in prevalence. Adverse outcomes of CKD can be prevented through early detection and treatment. There is limited data on the awareness...